PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2019 RESULTS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Cantor Fitzgerald Reiterates Overweight Rating on Pfizer (PFE) Following 4Q
January 29, 2020 7:04 AM ESTCantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $53.00 price target on Pfizer (NYSE: PFE) following the company's 4Q earnings report. PFE reported 4Q19 adjusted diluted EPS of $0.55, $0.03 lower than consensus.
PFE presented its 2020 sales and EPS guidance of $48.5-50.5B and... More
Pfizer (PFE) CEO, Never Says Never, But We Don't Want Big M&A - Bloomberg, Citing Call
January 28, 2020 10:59 AM ESTPfizer (NYSE: PFE) CEO, Never Says Never, But We Don't Want Big M&A - Bloomberg, Citing Call
Pfizer (PFE) Misses Q4 EPS by 2c, Offers FY20 Guidance
January 28, 2020 6:47 AM ESTPfizer (NYSE: PFE) reported Q4 EPS of $0.55, $0.02 worse than the analyst estimate of $0.57. Revenue for the quarter came in at $12.7 billion versus the consensus estimate of $12.61 billion.
GUIDANCE:
Pfizer sees FY2020 EPS of $2.82-$2.92, versus the consensus of $2.90. Pfizer sees... More
